Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Arundic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.88 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.75 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arundic Acid SCHEMBL28654238 | 1.00 | CA2 (0.88) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL11673146 | 1.00 | CA2 (0.88) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| Arundic Acid SCHEMBL30430550 | 0.96 | CA2 (0.81) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| Arundic Acid SCHEMBL30173360 | 0.96 | CA2 (0.81) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL11672845 | 0.96 | CA2 (0.81) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL15387920 | 0.96 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL689372 | 0.96 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL1963319 | 0.96 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL321981 | 0.96 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL15387941 | 0.96 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1889942-A | Drug containing (2R)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO (JP) | 2007-01-03 | — | — | CN | claimed |
| EP-1669065-A1 | DRUG CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | claimed |
| EP-1669065-B1 | DRUG CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-8053599-B2 | Drug containing (2R)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| CN-1889942-B | Drug containing (2R)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO | 2010-12-15 | — | — | CN | disclosed |
| US-20080057115-A1 | Capsule Stable Against Mastication | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| CN-101001622-A | Capsule stable against mastication | ONO PHARMACEUTICAL CO (JP) | 2007-07-18 | — | — | CN | disclosed |
| US-20070105956-A1 | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070066686-A1 | Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| EP-1754479-A1 | CAPSULE STABLE AGAINST MASTICATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-21 | — | — | EP | disclosed |
| CN-1889941-A | Infusion preparation comprising (2R) -2-propyloctanoic acid as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2007-01-03 | — | — | CN | disclosed |
| CN-1889942-A | Drug containing (2R)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO (JP) | 2007-01-03 | — | — | CN | disclosed |
| EP-1669065-A1 | DRUG CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1669066-A1 | INFUSION PREPARATION CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105956-A1 | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | PSEN2, PRNP, GRIK5 | CA2 26/4885CA1 279/4885NFKB1 546/4885 |
| US-20070066686-A1 | Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient | PARK7, IDE, ATP6V1B2 | CA2 196/4885CA1 221/4885NFKB1 848/4885 |
| US-20080057115-A1 | Capsule Stable Against Mastication | PGA5, HRH2, SI | CA2 275/4885CA1 584/4885NFKB1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.